A recent breakthrough in RNA vaccine technology is the development of self-amplifying RNAs. In this webinar, Dr. Mark Shulewitz, Field Application Scientist at GenScript, explains what self-amplifying RNAs are, how they differ from conventional RNA and their potential impact on shaping the next generation of RNA vaccines and other therapeutic applications.
Key Takeaways:
- IVT RNA has successfully been used for vaccines.
- Linear mRNA (conventional mRNA), Circular RNA (circRNA), self-amplifying RNA (saRNA) are the 3 modalities of RNA being explored for therapeutic applications.
- Self-amplifying RNA (saRNA) has higher and more prolonged protein expression than conventional mRNA.
- saRNA has great potential for vaccine and other therapeutic development.
- Higher protein expression
- Longer expression
- Requires lower dosage
- saRNA is in development for vaccines and can also be applied to other RNA-based applications such as protein replacement therapy.